Robbie Marcus
Stock Analyst at JP Morgan
(3.93)
# 555
Out of 4,893 analysts
161
Total ratings
55.45%
Success rate
8.59%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Downgrades: Neutral | $110 → $76 | $76.70 | -0.91% | 5 | May 30, 2025 | |
| NPCE NeuroPace | Maintains: Overweight | $14 → $16 | $10.17 | +57.33% | 5 | May 14, 2025 | |
| CVRX CVRx, Inc. | Downgrades: Underweight | $15 → $7 | $6.96 | +0.57% | 6 | May 9, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Overweight | $128 → $105 | $95.15 | +10.35% | 6 | May 6, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $12 | $13.17 | -8.88% | 6 | May 6, 2025 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $235 → $195 | $139.25 | +40.04% | 5 | May 6, 2025 | |
| CNMD CONMED | Maintains: Neutral | $70 → $58 | $53.57 | +8.27% | 7 | May 1, 2025 | |
| RXST RxSight | Downgrades: Underweight | $40 → $17 | $8.46 | +100.95% | 5 | Apr 4, 2025 | |
| MMSI Merit Medical Systems | Initiates: Overweight | $120 | $95.13 | +26.14% | 1 | Mar 28, 2025 | |
| BAX Baxter International | Maintains: Neutral | $38 → $36 | $29.70 | +21.21% | 17 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $445 | $394.77 | +12.72% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $526.05 | +28.31% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $7.38 | +76.15% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $110 | $103.86 | +5.91% | 13 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $330 | $297.40 | +10.96% | 4 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $32 | $16.76 | +90.93% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $32.06 | +24.77% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $78 | $78.80 | -1.02% | 4 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $85 | $85.46 | -0.54% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $76.50 | +17.65% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $35.94 | +39.12% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $6.22 | +28.62% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $243.87 | +2.51% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $16 | $9.41 | +70.12% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $7.32 | -4.31% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $14.20 | +19.72% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $133.60 | -11.68% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $134.71 | +15.80% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $105 | $89.40 | +17.45% | 11 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $106.55 | -62.46% | 2 | May 5, 2020 |
The Cooper Companies
May 30, 2025
Downgrades: Neutral
Price Target: $110 → $76
Current: $76.70
Upside: -0.91%
NeuroPace
May 14, 2025
Maintains: Overweight
Price Target: $14 → $16
Current: $10.17
Upside: +57.33%
CVRx, Inc.
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $6.96
Upside: +0.57%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Overweight
Price Target: $128 → $105
Current: $95.15
Upside: +10.35%
Integra LifeSciences Holdings
May 6, 2025
Maintains: Underweight
Price Target: $24 → $12
Current: $13.17
Upside: -8.88%
Inspire Medical Systems
May 6, 2025
Maintains: Overweight
Price Target: $235 → $195
Current: $139.25
Upside: +40.04%
CONMED
May 1, 2025
Maintains: Neutral
Price Target: $70 → $58
Current: $53.57
Upside: +8.27%
RxSight
Apr 4, 2025
Downgrades: Underweight
Price Target: $40 → $17
Current: $8.46
Upside: +100.95%
Merit Medical Systems
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $95.13
Upside: +26.14%
Baxter International
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $29.70
Upside: +21.21%
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $394.77
Upside: +12.72%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $526.05
Upside: +28.31%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $7.38
Upside: +76.15%
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $103.86
Upside: +5.91%
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $297.40
Upside: +10.96%
Nov 5, 2024
Initiates: Overweight
Price Target: $32
Current: $16.76
Upside: +90.93%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $32.06
Upside: +24.77%
Oct 25, 2024
Maintains: Neutral
Price Target: $72 → $78
Current: $78.80
Upside: -1.02%
Oct 25, 2024
Maintains: Neutral
Price Target: $75 → $85
Current: $85.46
Upside: -0.54%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $76.50
Upside: +17.65%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $35.94
Upside: +39.12%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $6.22
Upside: +28.62%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $243.87
Upside: +2.51%
Dec 20, 2023
Maintains: Neutral
Price Target: $10 → $16
Current: $9.41
Upside: +70.12%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $7.32
Upside: -4.31%
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $14.20
Upside: +19.72%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $133.60
Upside: -11.68%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $134.71
Upside: +15.80%
Dec 17, 2021
Downgrades: Neutral
Price Target: $130 → $105
Current: $89.40
Upside: +17.45%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $106.55
Upside: -62.46%